|
|
|
TESTOSTERONE BIOSYNTHETIC PATHWAY (PW:0000778)
DescriptionAndrogen hormones are responsible for the development and maintenance of male phenotype and reproductive functions and a range of other processes in nonreproductive tissues. Testosterone, the main androgen, is primarily synthesized in the testes; others are synthesized in the adrenal gland and can be converted to testosterone in peripheral tissues. Like all steroid hormones, androgens are derived from cholesterol; their biosynthesis is tightly regulated by the hypothalamus-pituitary-gonadal axis. The chronic steroidogenic response involves the change in the expression of steroidogenic genes while the acute response involves the quick delivery of cholesterol to the site of the first enzymatic reaction. The rapid flux of cholesterol from the outer (OMM) to the inner (IMM) mitochondrial membrane is mediated by the StAR protein. The IMM is the site where Cyp11a1, the enzyme catalyzing the first and rate-limiting step in the steroid biosynthetic pathway, is located. Overall there are two major classes of enzymes: the heme-containing cytochrome P450 and the hydroxysteroid dehydrogenase enzymes. The members of P450 superfamily that participate in the pathway are membrane-bound mitochondrial or endoplasmic reticulum (microsome) enzymes that utilize NADPH as an electron donor. Two proteins mediate the mitochondrial electron transfer - the flavin containing Fdxr and the iron-sulfur Fdx1; only one protein mediates the microsomal electron transfer - the P450 (cytochrome) oxidoreductase Por with two flavin cofactors. Dehydrogenases are membrane-bound mitochondrial or microsomal enzymes that utilize NAD or NADPH depending on whether the reaction is oxidation or reduction. The 27-carbon cholesterol is converted to the C 21 pregnenolone in a series of three chemical reactions that together constitute the step catalyzed by Cyp11a1. Cyp17a1 catalyzes the conversion of pregnenolone to 17OH-pregnenolone; in a second step, 17OH-pregnenolone is cleaved at the C 17-C 20 bond by the lyase activity of the enzyme to produce the C 19 androgen dehydroepiandrosterone (DHEA). Cyp17a1 can also convert the pregnenolone derived progesterone to 17OH-progesterone which is then cleaved to C 19 androstenedione. This route (not shown) is insignificant in humans but it is used by other species. DHEA can be sulfonated to DHEAS by Sult2a; the reverse reaction is caried out by steroid sulfatase Sts. DHEAS:DHEA ratio links to physiological as well as pathophysiological states. DHEA is converted to androstenediol or to androstenedione by hydroxysteroid dehydrogenase Hsd17b3, and Hsd3b1 or Hsd3b2, respectively. Androstenediol and androstenedione are then converted to testosterone by the action of Hsd3b1 or Hsd3b2, and Hsd17b3, respectively. Testosterone can be oxidized and thus inactivated to its androstenedione precursor by the action of Hsd17b2. In some of the target tissues, testosterone can be converted into its very potent metabolite dihydrotestosterone (DHT) by steroid-5-alpha reductases. DHT has a greater affinity for the androgen receptor and thus is a more powerful initiator of the androgen signaling pathway. To see the ontology report for annotations, GViewer and download, click here
The testosterone biosynthetic pathway is part of the Steroid Hormone Biosynthesis Pathway Suite and the Prostate Cancer Pathway Suite. Click the name of the suite to view the related pathways. ...(less)
|
Pathway Diagram:
|
|
|
Genes in Pathway:
testosterone biosynthetic pathway
|
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
|
ISS |
8 |
61,793,976 |
61,805,308 |
RGD:2325883 |
RGD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
|
ISS |
1 |
251,965,458 |
251,971,449 |
RGD:2325883 |
RGD |
| G |
Fdx1 |
ferredoxin 1 |
|
|
ISS |
8 |
55,291,396 |
55,310,507 |
RGD:2325883 |
RGD |
| G |
Fdxr |
ferredoxin reductase |
|
|
ISS |
10 |
105,342,684 |
105,351,374 |
RGD:2325883 |
RGD |
| G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
|
|
ISS |
19 |
47,729,519 |
47,802,933 |
RGD:4889549 |
RGD |
| G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
|
|
ISS |
17 |
6,554,164 |
6,585,525 |
RGD:2325883 |
RGD |
| G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
|
|
ISS |
2 |
193,337,342 |
193,346,799 |
RGD:4889549 |
RGD |
| G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
|
|
ISS |
2 |
193,500,916 |
193,507,633 |
RGD:4889549 |
RGD |
| G |
Por |
P450 (cytochrome) oxidoreductase |
|
|
ISS |
12 |
22,078,629 |
22,097,301 |
RGD:2325883 |
RGD |
| G |
Srd5a1 |
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) |
|
|
ISS |
17 |
3,845,190 |
3,879,165 |
RGD:2325883 |
RGD |
| G |
Srd5a2 |
steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) |
|
|
ISS |
6 |
21,453,521 |
21,489,408 |
RGD:2325883 |
RGD |
| G |
Star |
steroidogenic acute regulatory protein |
|
|
TAS |
16 |
70,642,580 |
70,647,203 |
RGD:2325883 |
RGD |
| G |
Sts |
steroid sulfatase (microsomal), isozyme S |
|
|
ISS |
X |
63,915,803 |
63,923,834 |
RGD:6893583 |
RGD |
| G |
Sult2a1 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 |
|
|
ISS |
1 |
75,632,632 |
75,708,022 |
RGD:2325883 |
RGD |
|
|
|
Pathway Gene Annotations |
|
Disease Annotations Associated with Genes in the testosterone biosynthetic pathway
|
|
|
|
| Cyp11a1 | Adrenal Hyperplasia, Congenital , Adrenal Insufficiency , Brain Injuries , Cardiomegaly , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Fetal Growth Retardation , Hyperglycemia , Hypertension , Hypogonadism , Nephrosis , Sciatic Neuropathy , Status Epilepticus | | Cyp17a1 | Adrenal Hyperplasia, Congenital , Adrenal hyperplasia, congenital, type 5 , Breast Neoplasms , Cholelithiasis , Gallbladder Neoplasms , Osteoporosis , Pancreatic Neoplasms , Polycystic Ovary Syndrome , Prostatic Neoplasms , Sciatic Neuropathy | | Fdx1 | Pancreatitis | |
|
| Hsd17b3 | 17-Hydroxysteroid Dehydrogenase Deficiency , Alzheimer Disease , Diabetes Mellitus, Type 2 , Disorders of Sex Development | | Hsd3b1 | Hyperprolactinemia , Hypertension | | Hsd3b2 | Adrenal hyperplasia 2 , Adrenal Hyperplasia, Congenital , Alzheimer Disease , Diabetes Mellitus, Type 2 , Hyperprolactinemia , Hypertension , Hypogonadism , Hypospadias , Hypothyroidism , Polycystic Ovary Syndrome , Sciatic Neuropathy | | Por | Adrenal Hyperplasia, Congenital , ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS , Disordered Steroidogenesis Due To Cytochrome P450 Oxidoreductase Deficiency , Hypotension , Musculoskeletal Abnormalities , Neural Tube Defects | | Srd5a1 | Breast Neoplasms , Cardiomegaly , Diabetes Mellitus, Type 2 , Hyperprolactinemia , Hypothyroidism , Obesity , Prostatic Hyperplasia , Prostatic Neoplasms | | Srd5a2 | Breast Neoplasms , Diabetes Mellitus , Hyperprolactinemia , Hypospadias , Penis agenesis , Prostatic Neoplasms , Pseudovaginal perineoscrotal hypospadias , Urogenital Abnormalities | | Star | Adrenal Hyperplasia, Congenital , Cardiomegaly , Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Fetal Growth Retardation , Fever , Hypogonadism , Hypothyroidism , Lipoid congenital adrenal hyperplasia , Nephrosis , Polycystic Ovary Syndrome , Toe Syndactyly, Telecanthus, and Anogenital and Renal Malformations | | Sts | Cryptorchidism , Hypertension , Ichthyosis, X-Linked | | Sult2a1 | Prostatic Neoplasms | |
| Pancreatic Neoplasms | Cyp17a1 | | Diabetes Mellitus | Srd5a2 | | Osteoporosis | Cyp17a1 | | Hypospadias | Hsd3b2 , Srd5a2 | | Fetal Growth Retardation | Cyp11a1 , Star | | Hyperprolactinemia | Srd5a1 , Hsd3b1 , Hsd3b2 , Srd5a2 | | Obesity | Srd5a1 | | Hypogonadism | Cyp11a1 , Hsd3b2 , Star | | Diabetes Mellitus, Type 2 | Srd5a1 , Cyp11a1 , Hsd17b3 , Hsd3b2 , Star | | Musculoskeletal Abnormalities | Por | | Neural Tube Defects | Por | | Cardiomegaly | Srd5a1 , Cyp11a1 , Star | | Cryptorchidism | Sts | | Urogenital Abnormalities | Srd5a2 | | Adrenal Insufficiency | Cyp11a1 | | Nephrosis | Cyp11a1 , Star | | Pseudovaginal perineoscrotal hypospadias | Srd5a2 | | Gallbladder Neoplasms | Cyp17a1 | | Hypothyroidism | Srd5a1 , Hsd3b2 , Star | | Adrenal Hyperplasia, Congenital | Cyp17a1 , Star , Por , Cyp11a1 , Hsd3b2 | | Fever | Star | | Breast Neoplasms | Cyp17a1 , Srd5a1 , Srd5a2 | | Disorders of Sex Development | Hsd17b3 | | Alzheimer Disease | Hsd17b3 , Hsd3b2 | | Penis agenesis | Srd5a2 | | Lipoid congenital adrenal hyperplasia | Star | | Hypertension | Hsd3b1 , Cyp11a1 , Hsd3b2 , Sts | | Prostatic Neoplasms | Cyp17a1 , Srd5a1 , Sult2a1 , Srd5a2 | | Prostatic Hyperplasia | Srd5a1 | | Polycystic Ovary Syndrome | Cyp17a1 , Hsd3b2 , Star | | Ichthyosis, X-Linked | Sts | | 17-Hydroxysteroid Dehydrogenase Deficiency | Hsd17b3 | | Adrenal hyperplasia 2 | Hsd3b2 | | Adrenal hyperplasia, congenital, type 5 | Cyp17a1 | | Brain Injuries | Cyp11a1 | | Cholelithiasis | Cyp17a1 | | Diabetes Mellitus, Experimental | Cyp11a1 , Star | | Hyperglycemia | Cyp11a1 | | Hypotension | Por | | Pancreatitis | Fdx1 | | Sciatic Neuropathy | Cyp17a1 , Cyp11a1 , Hsd3b2 | | Status Epilepticus | Cyp11a1 | | ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS | Por | | Disordered Steroidogenesis Due To Cytochrome P450 Oxidoreductase Deficiency | Por | | Toe Syndactyly, Telecanthus, and Anogenital and Renal Malformations | Star | |
|